A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
← catalyst calendarNCT06989437 · readout in 516 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
982estimated
Sites
214
Countries
Australia, Belgium, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-03 | actual | When the study began enrolling |
| Primary completion | 2028-01-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-10 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cachexia
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: ponsegromab
- Drug: placebo
Primary outcomes
what the primary-completion date above is the date OFPercent change from baseline in body weight for ponsegromab compared to placebo
measured Baseline, Week 12
Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores
measured Baseline, Week 12
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed